Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) closed at $0.41, down 13.01% in the latest trading session, significantly underperforming the S&P 500's 1.82% decline. The stock has fallen 6.58% over the past month while the Medical sector gained 5.28%. Upcoming earnings are expected to show an EPS of -$0.09 with revenue of $0.86 million, though full-year projections show mixed results. The company holds a Zacks Rank #3 (Hold) rating.